Recent Acquisition Impact Following its acquisition by Bausch Health in September 2025, DURECT Corporation is now part of a larger healthcare portfolio, presenting opportunities to leverage Bausch’s extensive distribution channels and customer base for DURECT’s pharmaceutical products.

Innovation and New Launches Bausch Health’s recent launch of Biafine Skin Recovery Emulsion and ongoing dermatology initiatives indicate significant focus on skin health and dermatological products, opening avenues to promote similar innovative formulations to dermatology clinics and medical professionals.

Market Presence and Events Participation in high-profile conferences like RBC Capital Markets and J.P. Morgan showcases Bausch’s active engagement with investors and industry leaders, providing potential partnership and collaboration opportunities for sales teams to align with strategic growth initiatives.

Financial and Legal Dynamics Despite recent legal challenges related to price-fixing allegations with multistate settlements, Bausch Health continues to invest in product development and community programs such as the ASPIRE HIGHER Scholarship, signaling resilience and commitment to growth and innovation, which can be emphasized in outreach efforts.

Employee and Leadership Strength The hiring of new directors like Eiry W. Roberts and ongoing research leadership changes demonstrate Bausch’s focus on strengthening executive expertise and R&D capabilities, creating opportunities to offer targeted solutions to support their innovation pipeline and operational needs.